Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in advanced renal cell cancer
NCT00073307Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Overall Survival at 33 months. Started Nov 2003; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00073307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073307.